Senseonics (NYSE:SENS) Trading Up 7.8%

Senseonics Holdings, Inc. (NYSE:SENS) shares shot up 7.8% during mid-day trading on Tuesday . The stock traded as high as $0.43 and last traded at $0.43. 1,628,010 shares changed hands during mid-day trading, a decline of 35% from the average session volume of 2,487,652 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Senseonics to a “sell” rating in a research note on Friday, March 29th.

Senseonics Stock Up 7.8 %

The firm has a market cap of $228.25 million, a P/E ratio of -3.91 and a beta of 0.87. The company’s fifty day moving average is $0.57. The company has a current ratio of 7.53, a quick ratio of 7.03 and a debt-to-equity ratio of 1.15.

Senseonics (NYSE:SENS) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Senseonics had a negative return on equity of 146.90% and a negative net margin of 270.13%. The company had revenue of $8.00 million for the quarter, compared to analysts’ expectations of $7.62 million. On average, sell-side analysts anticipate that Senseonics Holdings, Inc. will post -0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Ausdal Financial Partners Inc. lifted its holdings in Senseonics by 53.2% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock worth $43,000 after purchasing an additional 25,000 shares in the last quarter. RPO LLC purchased a new position in Senseonics in the 4th quarter worth approximately $37,000. Finally, Cornerstone Wealth Management LLC lifted its holdings in Senseonics by 55.9% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.